Original Articles, Reviews and Book Chapters:

1. Feig PU, Soter NA, Yager HM, Caplan L. Rosen S: Vasculitis with urticaria, hypocomplementemia, and multiple system involvement. JAMA 236:2065-2068,1976.

2. Feig PU, Wetzel GD, Frazier HS: Dependence of the driving force of the sodium pump on rate of transport. Am J Physiol 232:F448-F454, 1977.

3. Bennett WM, Singer I, Golper T, Feig P, Coggins CJ: Guidelines for drug therapy in renal failure. Ann Intern Med 86:754-783, 1977.

4. Feig PU, McCurdy DK: The hypertonic state. N Engl J Med 297:1444-1454, 1977.

5. McCurdy, DK, Feig, PU: Hyperosmolar coma (letter). N Engl J Med 248:855-856, 1978.

6. Feig, PU, Sterns, RH: Diagnosis of hypotonic states (letter). Ann Intern Med 88:717, 1978.

7. Mitnick PD, Feig PU: Control of hypertension and reversal of renal failure in scleroderma. N Engl J Med 299:871-872, 1978.

8. Sterns RH, Singer I, Feig PU: Presence of sodium transport inhibiting factor in dog plasma during volume expansion. Experientia 35:222-223, 1979.

9. Sterns RH, Feig PU, Pring M, Guzzo J, Singer I: The disposition of intravenous potassium in anuric man: A kinetic analysis. Kidney Int 15:651-660, 1979.

10. Rosenworcel E, Feig PU: An approach to proteinuria. Comprehensive Therapy 5:26-31, 1979.

11. Bennett WM, Murther RS, Parker RA, Feig PU, Morrison G, Golpher TA, Singer I: Drug therapy in renal failure: dosing guidelines for adults. Part I: Antimicrobial agents, analgesics. Ann Int Med 93:62-89, 1980.

12. Bennett WM, Murther RS, Parker RA, Feig PU, Morrison G, Golpher TA, Singer I: Drug therapy in renal failure: dosing guidelines for adults. Part II: Sedatives, hypnotics, and tranquilizers; cardiovascular, antihypertensive, and diuretic agents; miscellaneous agents. Ann Int Med 93:286-325, 1980.

13. Feig PU, Shook A, Sterns RH: The effect of potassium removal during hemodialysis on the plasma potassium concentration. Nephron 27:25-30, 1981.

14. Feig PU: Hypernatremia and hypertonic syndromes. In: Symposium on Body Fluid and Electrolyte Disorders. Philadelphia: W.B. Saunders, Med Clin North Am 65(2):271-290, 1981.

15. Sterns RH, Guzzo J. Feig PU: The disposition of intravenous potassium in normal man: The role of insulin. Clin Sci 61(1):23-38, 1981.

16. Sterns RH, Cox M, Feig PU, Singer I: Internal potassium balance in the control of plasma potassium concentration. Medicine 60:339-354, 1981.

17. Feig PU: Diabetes insipidus. In: Conn, HF, ed. Current Therapy, Philadelphia. W.B. Saunders, 1982.

18. Feig PU, Sterns RH: States of hyponatremia and hypernatremia. In: Flamenbaum W, Hamburger RJ, eds. Nephrology. An approach to the patient with renal disease. Philadelphia. J.B. Lippincott Co., 1982.

19. Feig PU, Mitchell PP, Abrutyn E, Brock SM, Carney WR, Graeber CW, Horak E, Lyons RW, Maher JF: Aminoglycoside nephrotoxicity: A double-blind prospective randomized study of gentamicin and tobramycin. J Antimicrob Chemoth 10:217-226, 1982.

20. Feig PU, Hirszel P, Galen MA, Rosenworcel E, Raisz L: Hemodialysis in the treatment of life-threatening hyperphosphatemia. Clin Exper Dial Apher 6:105-111, 1982.

21. Karimeddini MK, Feig PU, McAloon M: Radiosulfate determination of extracellular fluid volume in morbid obesity. Eur J Nucl Med 7:521-522, 1982.

22. Feig, PU: Divalent cations in essential hypertension (letter). N Engl J Med 311:605, 1984.

23. Chapron DJ, Sweeney KR, Feig PU, Kramer PA: Influence of advanced age on the disposition of acetazolamide. Brit J Clin Pharmac. 19:363-371, 1985.

24. Feig PU, Mitchell PP, Boylan JW: Erythrocyte Membrane Transport in Hypertensive Man and Rat: Effect of Sodium Depletion and Excess. Hypertension 7:423-429, 1985.

25. Feig, PU: Cellular mechanism of action of loop diuretics: Implications for drug effectiveness and adverse effects. Am J Cardiol. 57:14A-19A, 1986.

26. Sweeney KR, Chapron DJ, Brandt JL, Gomolin IH, Feig PU, Kramer PA: Toxic interaction between acetazolamide and salicylate: Case reports and a pharmacokinetic explanation. Clin Pharmacol Ther 40:518-524, 1986.

27. Feig PU, D'Occhio MA, Boylan JW: Increased Na-H exchange activity in neutrophils of spontaneously hypertensive rats. J of Hypertension 4:S224-S226, 1986.

28. Feig, PU: Adverse effects of loop diuretics: lessons from their cellular mechanism of action. In: Puschett JB, Greenberg A, eds. Diuretics II: Chemistry, pharmacology, and clinical applications. New York, Elsevier, 1987.

29. Feig PU, D'Occhio MA, Boylan JW: Lymphocyte membrane sodium-proton exchange in spontaneously hypertensive rats. Hypertension 9:282-288, 1987.

30. Feig, PU, Rutan, GH: The end of end-stage renal disease? Ann Intern Med. 111:451-453, 1989.

31. Feig, PU: Increased platelet membrane sodium-proton exchange rate in spontaneously hypertensive rats. Am J Hypertens 3:927-932,1990.

32. Boylan JW, Van Liew JB, Feig, PU: Inverse changes in erythroid cell volume and number regulate the hematocrit in newborn genetically hypertensive rats. Proc Natl Acad Sci 88:9848-9852,1991.

33. Carr AA, Bottini PB, Feig PU, Karlos ML, Schwartz LA, Mulligan S, DeVane JG, Fisher LD, Mac Carthy EP: Once-daily monotherapy of hypertension with nifedipine sustained release. Drug Invest 4:184-191,1992.

34. Carr AA, Bottini PB, Feig PU, Prisant M, Mulligan S, DeVane JG, Fisher L, Rhoades RB, Mac Carthy EP: Effectiveness of once-daily monotherapy with a new nifedipine sustained release calcium channel blocker. Am J Cardiol 69:28E-32E, 1992.

35. Ellis D, Banner B, Janosky JE, Feig PU: Potassium supplementation attenuates experimental hypertensive renal injury. J Am Soc Nephrol 2:1529-1537, 1992.

36. Rutan GH, Feig PU, May S, Kriegman AG, Brady EM: A comparison of once- daily atenolol and metoprolol using office and ambulatory blood pressure monitoring. J Clin Pharmacol 33:418-426, 1993.

37. Feig PU, Gibson L, Mac Carthy EP, Pettis PP, Schwartz L: The efficacy and safety of once daily nifedipine coat-core (Adalat CC) in the treatment of mild-to-moderate hypertension. Clinical Therapeutics 15:963-975, 1993.

38. Mac Carthy EP, Pettis PP, Gibson L, Schwartz L, Feig PU: The safety and efficacy of once daily nifedipine coat-core (Adalat CC) in combination with atenolol in hypertensive patients. Clinical Therapeutics 15:976-987, 1993.

39. Savage S, Estacio R, Feig PU, Mac Carthy EP, Luken NJ, Ziegler R, Schrier RW: Appropriate blood pressure control in diabetes (ABCD) trial. Submitted for publication.

40. Segal P, Ratzmann KP, Schernthaner G, Rybka J, Feig PU, Petzinna D: The efficacy and safety of miglitol therapy, compared to glibenclamide, in patients with NIDDM, inadequately controlled by diet alone. Diabetes Care 20:687-691, 1997.

41. Johnson PS, Feig PU, Coniff R, Krol A, Davidson J, Haffner S: Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic-American type 2 diabetic patients. Diabetes Care 21:409-415, 1998.

42. Johnson PS, Feig PU, Coniff RF, Krol A, Kelley DE, Mooradian AD: Chronic treatment of African-American type II diabetic patients with alpha-glucosidase inhibition. Diabetes Care 20:416-422, 1998.

Abstracts:

1. Feig PU, Wetzel GD, Frazier HS: Dependence of the driving force for active Na+ transport (ENa) on rate of transport. Clin Res 23:430A, 1975.

2. Feig PU, Wetzel GD, Frazier HS: Components of the observed active transport potential (ENa). Proc VI Int Congr Nephrol 210, 1975.

3. Sterns R, Guzzo J, Feig PU: Role of insulin in human K+ homeostasis. Kidney Int 12:475, 1977.

4. Sterns R, Feig PU, Pring M, Singer I: Control of K+ distribution kinetics in "anuric" humans. Kidney Int 12:574, 1977.

5. Sterns R, Feig PU, Singer I: Antinatriferic factor in plasma dialysates from volume expanded (E) and hydroponic (C) dogs: Effect on sodium transport in toad urinary bladder (TUB). Kidney Int 12:574, 1977.

6. Sterns R, Feig PU, Pring M, Singer I: Disposition of infused K+ in anuric humans: a kinetic analysis. Clin Res 26:476A, 1978.

7. Morrison G, Feig PU, Sterns RH, Guzzo J, Walker BR, Singer I: V. Cyclacillin pharmacokinetics: effects of renal failure and hemodialysis. Clin Res 26:292A, 1978.

8. Shook A, Sterns RH, Feig PU: The effect of K+ removal (KR) by hemodialysis on plasma K+: Relationship to the predialysis plasma K+ (PKo). Kidney Int 14:686, 1978.

9. Sterns RH, Feig PU: Disposition of intravenous K+ in normal man: Role of insulin. Clin Res 27:431A, 1979.

10. Mitchell PP, Hirszel P, Feig PU: Peritoneal permeability to small molecules in vitro. Am Soc Artif Intern Organs 9:55, 1980.

11. Feig PU, Mitchell PP, Stetson DL, Raymond LW: Do extreme changes in atmospheric pressures affect the normal osmoregulation? Kidney Int 19(1):239, 1981.

12. Mitchell PP, Feig PU: Lack of effect of prostaglandin E2 (PGE2) or arachiodonic acid (AA) on permeability of the rabbit peritoneum in vitro. Kidney Int 19(1):146, 1981.

13. Feig PU, Mitchell PP, Horak E, Carney W, Graeber C, Lyons R: Effect of gentamicin and tobramycin on serum creatinine and urinay N-acetyl-beta-glucosaminidase and beta-2-mitroglobulin. Clin Res 29(2):362A, 1981.

14. Feig PU, Mitchell PP, Sha'Afi R: Further characterization of the sodium transport abnormality found in red blood cells (RBC) of subjects with essential hypertension (EH). Kidney Int 21:187, 1982.

15. Feig PU, Mitchell PP, Boylan JW: Erythrocyte sodium transport in spontaneously hypertensive rats (SHR): effect of sodium depletion. Clin Res 30(2):335A, 1982.

16. Feig PU, Mitchell PP, Boylan JW: Membrane protein content, surface area and sodium flux in red blood cells (RBC) of spontaneously hypertensive rats (SHR). Kidney Int 23:169A, 1983.

17. Boylan JW, Mitchell PP, D'Occhio MA, Feig PU: Evidence for primary cellular vs. humoral cause for the sodium transport abnormality of red blood cells (RBC) of spontaneously hypertensive rats (SHR). Kidney Int 23:167A, 1983.

18. Sweeney KR, Chapron DJ, Kramer PA, Feig PU: Influence of advanced age on acetazolamide disposition. Presented at the 35th National Meeting, Academy of Pharmaceutical Sciences, 1983.

19. Feig PU, Mitchell PP, Sha'Afi RI: Calcium flux and content in leukocytes of spontaneously hypertensive and normotensive rats. Clin Res 32(2):330A, 1984.

20. Feig PU, D'Occhio MA, Boylan JW: Cell volume regulation and water content of normotensive Wistar-Kyoto (WKR) and spontaneously hypertensive rats (SHR). Kidney Int. 27:190, 1985.

21. Feig PU, D'Occhio MA, Boylan JW: Membrane sodium-proton exchanger activity in spontaneously hypertensive rats. Clin Res 33(2):361A, 1985.

22. Sweeney KR, Chapron DJ, Feig PU, Kramer PA: In vivo interaction between acetazolamide and salicylate. 39th Annual Meeting of the American Pharmaceutical Association/Academy of Pharmaceutical Sciences, 1985.

23. Sweeney KR, Chapron DJ, Feig PU, Kramer PA: Cooperative in vivo interaction between acetazolamide and flurbiprofen. 39th Annual Meeting of the American Pharmaceutical Association/Academy of Pharmaceutical Sciences, 1985.

24. Feig PU, D'Occhio MA, Boylan JW: Characterization of the cell membrane Na/H exchange in spontaneously hypertensive rats (SHR). Kidney Int 29:245, 1986.

25. Feig PU, D'Occhio MA, Boylan JW: Increased Na-H exchange activity in neutrophils of spontaneously hypertensive rats (SHR). Abstracts of the First Annual Meeting of the American Society of Hypertension, 30A, 1986.

26. Feig PU: Membrane Na-H exchange in platelets of spontaneously hypertensive rats (SHR). Kidney Int 31:296, 1987.

27. Feig PU: Increased Na-H exchange activity in platelets of spontaneously hypertensive rats (SHR). Second Annual Meeting of the American Society of Hypertension, 1987.

28. Romovacek M, Moody E, Feig PU: Effects of dietary Na and K on blood pressure and heart weight in Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR). Council for High Blood Pressure Research, AHA, 1989.

29. Ellis D, Banner B, Johnston JR, Feig PU: Chronic dietary Na+ supplementation aggravates and K+ ammeliorates albuminuria in spontaneously hypertensive rats (SHR). Kidney Int. 37:384, 1990.

30. Feig PU, Leer M, Nie S: Intracellular pH (pHi) in platelets is lower in spontaneously hypertensive (SHR) than in Wistar Kyoto (WKY) rats. Kidney Int 37:385, 1990.

31. Feig PU, Kubisty CA, Romovacek M, Moody E: Effects of Dietary Na and K on blood pressure and heart weight in Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR). Am J Hypertens 3:1A, 1990.

32. Feig PU, Kubisty CA, Romovacek M, Moody E: Effects of Dietary Na and K on blood pressure and heart weight in Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR). J Hypertension 8:S50, 1990.

33. Ellis D, Banner B, Feig PU: Potassium supplementation attenuates renal injury without altering systemic blood pressure (SBP) in spontaneously hypertensive rats (SHR). Am J Hypertens 3:64A, 1990.

34. Feig PU, Gibson L, Mac Carthy EP, Walsh PP: Safety and efficacy of a new once-daily nifedipine coat-core formulation (NIF CC) for the treatment of hypertension. 14th Mtg., Int. Soc. Hypert. 1992.

35. Mac Carthy EP, Walsh PP, Gibson L, Feig PU: Safety and efficacy of a new once-daily nifedipine coat-core formulation (NIF CC) in combination with atenolol (ATN) for the treatment of hypertension. 14th Mtg., Int. Soc. Hypert. 1992.

36. White WB, Feig PU, Karlos ML, Mac Carthy EP, Walsh PP: Safety and efficacy of a new once-daily nifedipine slow-release formulation (NIF SR) compared to verapamil SR (VER SR) for the treatment of hypertension. Am J Hypertens 5:110A, 1992.

37. Hall WD, Blackburn KL, Feig PU, Walsh PP, Mac Carthy EP: Safety and efficacy of a new once-daily nifedipine slow-release formulation (NIF SR) compared to lisinopril (LIS) for the treatment of hypertension in elderly patients. Am J Hypertens 5:115A, 1992.

38. Feig PU, Shannon T, Gibson L, Mac Carthy EP, Walsh PP: Safety and efficacy of a new once-daily nifedipine coat-core formulation (NIF CC) for the treatment of hypertension. Am J Hypertens 6:129A, 1993.

39. Mac Carthy EP, Walsh PP, Gibson L, Feig PU: Safety and efficacy of a new once-daily nifedipine coat-core formulation (NIF CC) in combination with atenolol (ATN) for the treatment of hypertension. Am J Hypertens 6:129A, 1993.

40. Savage S, Feig PU, Kostka L, Lukken N, Schrier RW: Correlation between microalbuminuria and micro- and macro-angiopathic complications in type II diabetes mellitus. XIII International Congress of Nephrology, Jerusalem, Israel, 1993.

41. Drent ML, Van der Veen EA, Branolte J, Feig PU: Miglitol as a single oral hypoglycemic agent in NIDDM. 54th Scientific Session of the American Diabetes Association, New Orleans, Louisiana, 1994.

42. McCarron DA, Gilbert JC, Pettis PP, Haverstock D, Feig PU, Mac Carthy EP: A multi-center, placebo-controlled study of once-daily treatment with nisoldipine coat-core vs verapamil sustained release bid in hypertension. Am J Hypert 7:A, 1994.

43. Burris JF, Gilbert JC, Pettis PP, Haverstock D, Feig PU, Mac Carthy EP: A multi-center, placebo-controlled study of once-daily treatment with nisoldipine coat-core in combination with atenolol in hypertension. Am J Hypert 7:A, 1994.

44. Weber MA, Gilbert JC, Pettis PP, Valalik E, Feig PU, Mac Carthy EP: A multi-center, placebo-controlled study of once-daily treatment with nisoldipine coat-core in hypertension. Am J Hypert 7:A, 1994.

45. Ratzmann KP, Feig PU, Petzinna D, Rybka J, Schernthaner G, Segal P: Treatment of non-insulin-dependent diabetes mellitus: miglitol versus glibenclamide versus placebo. Diabetologia 38:A199, 1995.

46. Johnston P, Feig P, Coniff R: Treatment of Afro-American NIDDM patients with alpha-glucosidase inhibition. Submitted to the 57th Scientific Session of the American Diabetes Association, Boston, 1997.

47. Davidson J, Johnston P, Feig P, Coniff R: Treatment of Hispanic-American NIDDM patients with alpha-glucosidase inhibition. Submitted to the 57th Scientific Session of the American Diabetes Association, Boston, 1997.